Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies Read more about Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies
Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency Read more about Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency
Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma Read more about Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma
Agios to Present New Data from PKR and IDH Programs at the 2016 ASH Annual Meeting Read more about Agios to Present New Data from PKR and IDH Programs at the 2016 ASH Annual Meeting
Agios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs Read more about Agios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs
Agios to Present at the 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8, 2016 Read more about Agios to Present at the 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8, 2016
Agios to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016 Read more about Agios to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016
Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML Read more about Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Read more about Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Agios Announces Pricing of $150 Million Public Offering of Common Stock Read more about Agios Announces Pricing of $150 Million Public Offering of Common Stock